Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIPNYSE:DNANASDAQ:GPCRNASDAQ:IMCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$70.82+0.8%$66.45$52.50▼$73.72$1.54B0.56286,485 shs287,058 shsDNAGinkgo Bioworks$7.40+14.7%$7.14$5.00▼$38.58$429.16M1.291.47 million shs1.79 million shsGPCRStructure Therapeutics$26.53+4.8%$20.78$13.22▼$62.74$1.52B-1.69924,997 shs536,165 shsIMCRImmunocore$29.92+6.6%$28.81$23.15▼$61.99$1.50B0.75428,260 shs287,056 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals+0.78%0.00%+5.72%+17.66%+6.15%DNAGinkgo Bioworks+14.60%+0.34%+15.66%-45.78%-79.25%GPCRStructure Therapeutics+4.79%-1.73%+85.42%-11.61%-32.53%IMCRImmunocore+6.63%-0.60%+13.85%-0.17%-50.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIPANI Pharmaceuticals4.4876 of 5 stars3.53.00.03.33.33.31.3DNAGinkgo Bioworks0.7207 of 5 stars0.81.00.00.02.42.51.3GPCRStructure Therapeutics2.3511 of 5 stars3.51.00.00.04.01.70.6IMCRImmunocore3.1471 of 5 stars4.21.00.00.03.54.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 3.00Buy$80.1313.14% UpsideDNAGinkgo Bioworks 1.60Reduce$4.58-38.13% DownsideGPCRStructure Therapeutics 3.00Buy$78.63196.32% UpsideIMCRImmunocore 2.45Hold$59.4498.68% UpsideCurrent Analyst Ratings BreakdownLatest DNA, ANIP, GPCR, and IMCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025GPCRStructure TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.004/22/2025GPCRStructure TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.004/21/2025ANIPANI PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$62.00 ➝ $65.004/14/2025IMCRImmunocoreJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$54.00 ➝ $50.004/11/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.004/10/2025IMCRImmunocoreNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$71.00 ➝ $71.004/7/2025IMCRImmunocoreMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$38.00 ➝ $33.003/17/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$94.00 ➝ $94.003/14/2025ANIPANI PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.003/12/2025ANIPANI PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$85.003/12/2025IMCRImmunocoreNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$71.00 ➝ $71.00(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$614.38M2.51$7.84 per share9.03$21.13 per share3.35DNAGinkgo Bioworks$227.04M1.89N/AN/A$21.93 per share0.34GPCRStructure TherapeuticsN/AN/AN/AN/A$9.77 per shareN/AIMCRImmunocore$310.20M4.83N/AN/A$7.42 per share4.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals$18.78M-$1.14N/A16.82N/A-1.28%15.87%6.88%5/9/2025 (Estimated)DNAGinkgo Bioworks-$892.87M-$10.68N/AN/AN/A-298.78%-58.54%-34.24%N/AGPCRStructure Therapeutics-$89.62M-$0.79N/AN/AN/AN/A-16.37%-15.68%5/8/2025 (Estimated)IMCRImmunocore-$55.29M-$1.02N/AN/AN/A-15.87%-12.84%-5.09%N/ALatest DNA, ANIP, GPCR, and IMCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025ANIPANI Pharmaceuticals$1.37N/AN/AN/A$179.75 millionN/A5/8/2025Q1 2025GPCRStructure Therapeutics-$0.24N/AN/AN/AN/AN/A5/7/2025Q1 2025IMCRImmunocore-$0.35$0.10+$0.45$0.10$108.82 million$125.13 million5/6/2025Q1 2025DNAGinkgo Bioworks-$1.23-$1.58-$0.35-$1.68$38.70 million$48.32 million2/27/2025Q4 2024GPCRStructure Therapeutics-$0.23-$0.22+$0.01-$0.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.522.741.97DNAGinkgo BioworksN/A5.795.79GPCRStructure TherapeuticsN/A27.6327.63IMCRImmunocore1.033.783.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%DNAGinkgo Bioworks78.63%GPCRStructure Therapeutics91.78%IMCRImmunocore84.50%Insider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals12.70%DNAGinkgo Bioworks9.72%GPCRStructure Therapeutics9.43%IMCRImmunocore10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60021.77 million18.36 millionOptionableDNAGinkgo Bioworks64058.03 million51.89 millionOptionableGPCRStructure Therapeutics13657.34 million51.86 millionOptionableIMCRImmunocore32050.07 million45.48 millionOptionableDNA, ANIP, GPCR, and IMCR HeadlinesRecent News About These CompaniesImmunocore stock rises as Q1 results top estimatesMay 7 at 1:16 PM | investing.comCompared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key MetricsMay 7 at 10:36 AM | zacks.comImmunocore reports first quarter financial results and provides a business updateMay 7 at 7:00 AM | globenewswire.comMarshall Wace LLP Reduces Holdings in Immunocore Holdings plc (NASDAQ:IMCR)May 3, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Acquires 29,832 Shares of Immunocore Holdings plc (NASDAQ:IMCR)May 1, 2025 | marketbeat.comImmunocore (NASDAQ:IMCR) & Coeptis Therapeutics (NASDAQ:COEP) Head-To-Head SurveyMay 1, 2025 | americanbankingnews.comWall Street Analysts Think Immunocore (IMCR) Could Surge 107.45%: Read This Before Placing a BetApril 30, 2025 | zacks.comWells Fargo & Company MN Sells 11,120 Shares of Immunocore Holdings plc (NASDAQ:IMCR)April 28, 2025 | marketbeat.comImmunocore Holdings: A Name On My Watch ListApril 27, 2025 | seekingalpha.comRenaissance Technologies LLC Sells 179,630 Shares of Immunocore Holdings plc (NASDAQ:IMCR)April 27, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Buys 200,373 Shares of Immunocore Holdings plc (NASDAQ:IMCR)April 26, 2025 | marketbeat.comLegal & General Group Plc Acquires 20,163 Shares of Immunocore Holdings plc (NASDAQ:IMCR)April 25, 2025 | marketbeat.comImmunocore (NASDAQ:IMCR) Stock Price Down 2.4% - What's Next?April 24, 2025 | marketbeat.comJump Financial LLC Has $962,000 Stake in Immunocore Holdings plc (NASDAQ:IMCR)April 24, 2025 | marketbeat.comImmunocore (NASDAQ:IMCR) Stock Price Up 5% - Here's WhyApril 23, 2025 | marketbeat.comImmunocore Holdings plc (NASDAQ:IMCR) Given Average Rating of "Moderate Buy" by AnalystsApril 17, 2025 | marketbeat.comImmunocore (NASDAQ:IMCR) Given New $50.00 Price Target at JPMorgan Chase & Co.April 16, 2025 | marketbeat.comFmr LLC Sells 18,341 Shares of Immunocore Holdings plc (NASDAQ:IMCR)April 15, 2025 | marketbeat.comJ.P. Morgan Remains a Buy on Immunocore Holdings (IMCR)April 15, 2025 | markets.businessinsider.comImmunocore (NASDAQ:IMCR) Receives "Buy" Rating from Needham & Company LLCApril 12, 2025 | marketbeat.comImmunocore (NASDAQ:IMCR) Reaches New 12-Month Low - Should You Sell?April 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDNA, ANIP, GPCR, and IMCR Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$70.82 +0.55 (+0.78%) Closing price 05/7/2025 04:00 PM EasternExtended Trading$70.42 -0.40 (-0.57%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Ginkgo Bioworks NYSE:DNA$7.40 +0.95 (+14.65%) Closing price 05/7/2025 03:59 PM EasternExtended Trading$7.60 +0.20 (+2.70%) As of 04:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Structure Therapeutics NASDAQ:GPCR$26.53 +1.20 (+4.75%) Closing price 05/7/2025 03:59 PM EasternExtended Trading$26.54 +0.01 (+0.02%) As of 05/7/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Immunocore NASDAQ:IMCR$29.92 +1.86 (+6.63%) Closing price 05/7/2025 04:00 PM EasternExtended Trading$29.90 -0.02 (-0.05%) As of 04:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Lemonade Delivers Sweet Results, Price Reversal to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
